DSM B.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
14 feb 2007 - 08:01
Statutaire naam
DSM B.V.
Titel
DSM achieves record sales and operating profit in 2006, ahead of Vision 2010 objectives
Bericht
• Operating profit for 2006 EUR 835 million, 6% higher than in 2005.
• Net profit EUR 547 million, up 4% from 2005.
• Solid volume growth (5%), especially in Performance Materials (9%).
• Proposed dividend EUR 1.00 per ordinary share.
• Outlook: Operating profit in 2007 expected to be lower than in 2006, but on track with Vision 2010.
DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6® technology platform.
Royal DSM N.V. and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announce fermentation yields of more than 10 grams per liter for monoclonal antibodies, a major breakthrough in the development of their PER.C6 technology platform.
Datum laatste update: 24 februari 2026